Skip to main content
Clinical Trials/NCT05534217
NCT05534217Not yet recruitingNot Applicable

A Prospective, Randomized, Double-blind, Controlled Clinical Study of Corneal Debridement to Treat the Traumatic Corneal Abrasion

Zhongshan Ophthalmic Center, Sun Yat-sen University1 site in 1 country156 target enrollmentStarted: December 31, 2022Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
156
Locations
1
Primary Endpoint
wound recurrence

Study Overview

Brief Summary

Patients who signed informed consent to participate in the study will receive corneal epithelial deplasia. The patient was instructed to follow up closely in the following year, and the recurrence of the patient was collected through wechat follow-up.

Detailed Description

Traumatic corneal abrasion (TCA) refers to the injury or defect of the corneal epithelium caused by a foreign object (such as a nail, a tree branch, etc.), which is characterized by severe eye pain accompanied by red eyes, blepharospasm, photophobia, tearing, and a distinct foreign body sensation. TCA is one of the common eye injuries and ophthalmic emergencies, accounting for about 5%-10% in ophthalmic emergencies. Methods: The investigators conducted a clinical trial in adult patients with corneal trauma at the Zhongshan Ophthalmology Center of Sun Yat-sen University. Patients who signed informed consent to participate in the study were provided with corneal epithelial debridement. Patients were instructed to follow closely for the following year, and a pain log of the patient was collected at the last ophthalmology clinic visit.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Double (Participant, Outcomes Assessor)

Masking Description

The participants didn't know where they were grouped,and the experimenters did not know about the trial either.

Eligibility Criteria

Ages
18 Years to 60 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • The affected eye is traumatic corneal epithelial abrasion, and the specific criteria are as follows: A: Damage caused by one of the three high risk causes of recurrent corneal epithelial exfoliation defined as fingernails, paper, or plant leaves; B: Monocular disease; C: Eye pain, tears, photophobia and foreign body sensation when injured; D: Local defect of corneal epithelium was found at the time of injury, and fluorescein sodium staining was positive; E: The time from injury to first diagnosis is less than 24 hours.
  • Be between the ages of 18 and
  • Patients volunteered to participate in the study and signed the informed consent, showing good compliance.

Exclusion Criteria

  • Corneal epithelial defect complicated with infection.
  • Patients with other ocular surface diseases (such as eyelid insufficiency, eyelid gland dysfunction, Sjogren's syndrome, bullae keratopathy, corneal dystrophy, drug induced corneal toxicity, etc.).
  • Pre-existing corneal disease (corneal degenerative disease or viral keratitis, etc.) or history of corneal surgery;
  • Long-term contact lens wearers.
  • Pregnant or lactating women; Severe impairment of heart, liver and kidney function; One who is mentally abnormal; People with other inflammatory or autoimmune diseases. Corneal epithelial defect complicated with infection

Arms & Interventions

debridement+traditional treatment

Experimental

The experimental group receives debridement of the abrasion wound before receiving traditional treatment including evofloxacin eye drops + befushu QID * for 14 days, four times a day, and the corneal contact lens was worn for 2 weeks.

Intervention: corneal debridement of corneal abrasion (Biological)

traditional treatment

Active Comparator

The traditional group receives evofloxacin eye drops + befushu QID * for 14 days, four times a day, and the corneal contact lens was worn for 2 weeks.

Intervention: corneal debridement of corneal abrasion (Biological)

Outcomes

Primary Outcomes

wound recurrence

Time Frame: month 12 after treatment

Wound recurrence during 12 months after treatment.

Secondary Outcomes

  • Incidence of wound infection(week 1, week 2, month 1, month 2, month 3, month 6, month 9, and month 12.)
  • The grading of pain for eyes(week 1, week 2, month 1, month 2, month 3, month 6, month 9, and month 12.)
  • Corneal scar(week 1, week 2, month 1, month 2, month 3, month 6, month 9, and month 12.)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials